{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:33:42Z","timestamp":1790948022117,"version":"4.1.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n \n Clostridioides difficile<\/jats:italic>\n infection (CDI) is associated with substantial morbidity and mortality, and recurrent CDI (rCDI) is common.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether a 4-week vancomycin pulse and taper regimen would be superior to a standard 2-week vancomycin pulse regimen in terms of recurrence.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This parallel-design, double-blind clinical trial was performed at 12 Canadian hospitals. Adults with a first episode or first recurrence of CDI were eligible to participate. Patients needed to have clinical CDI with laboratory confirmation and to have improved by day 10 of treatment. Recruitment began November 19, 2020, and all follow-up was completed by October 4, 2024.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n All patients received a 2-week pulse of vancomycin (standardized at 125 mg orally 4 times a day at the time of recruitment) and were then randomized to receive either vancomycin taper (125 mg orally twice a day for 7 days and then 125 mg once a day for 7 days) or an equivalent schedule of placebo capsules.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the posterior probability of superiority of the vancomycin pulse and taper regimen to prevent rCDI at day 56. A secondary outcome was recurrence at day 38. Binary outcomes were analyzed using a bayesian generalized linear model with minimally informative priors yielding log relative risk (RR) with 95% bayesian credible intervals (CrIs).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The trial was stopped early due to feasibility of recruitment. Among 265 participants (135 in the intervention group and 130 in the control group; median age, 63 [IQR 47-74] years; 138 [52.1%] women), recurrence at day 56 occurred in 20 of 135 patients (14.8%) in the vancomycin pulse and taper group compared with 23 of 130 (17.7%) in the vancomycin pulse group (adjusted RR, 0.84 [95% CrI, 0.48-1.45]; posterior probability of superiority, 73.8%). Recurrence at day 38 occurred in 9 of 135 patients (6.7%) in the vancomycin pulse and taper group compared with 20 of 130 (15.4%) in the vancomycin pulse group (adjusted RR, 0.43 [95% CrI, 0.19-0.89]; posterior probability of superiority, 99.0%). Adverse effects were rare in both groups.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, a 4-week vancomycin pulse and taper regimen had a probability of 73.8% to be superior to a 2-week pulse regimen. This approach may represent a safe and accessible treatment option to delay or prevent early CDI recurrence.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04138706<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.60495","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:30:33Z","timestamp":1772209833000},"page":"e2560495","source":"Crossref","is-referenced-by-count":8,"title":["Initial Vancomycin Taper for the Prevention of Recurrent\n Clostridioides difficile<\/i>\n Infection"],"prefix":"10.1001","volume":"9","author":[{"given":"Emily G.","family":"McDonald","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, McGill University, Montr\u00e9al, Quebec, Canada"},{"name":"Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Butler-Laporte","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Brophy","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Bioethics, and Occupational Health, McGill University, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Elsayed","sequence":"additional","affiliation":[{"name":"Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Frenette","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Huseen","sequence":"additional","affiliation":[{"name":"Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian G.","family":"Loo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Moran","sequence":"additional","affiliation":[{"name":"Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Coburn","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susy S.","family":"Hota","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Longtin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling Y.","family":"Kong","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Muller","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, The University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore S.","family":"Steiner","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Valiquette","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Diseases, Universit\u00e9 de Sherbrooke, Sherbrooke, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Daneman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, The University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Daley","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Memorial University, St John\u2019s, Newfoundland, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Nott","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek R.","family":"MacFadden","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E.","family":"Kandel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Michael Garron Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, Temerity Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Perez-Patrigeon","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montr\u00e9al, Quebec, Canada"},{"name":"Division of Infectious Diseases, Department of Medicine, McGill University, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"TAPER-V Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire J.","family":"Lin","sequence":"additional","affiliation":[{"name":"for the TAPER-V Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaz J.","family":"Idris","sequence":"additional","affiliation":[{"name":"for the TAPER-V Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne K.","family":"Chan","sequence":"additional","affiliation":[{"name":"for the TAPER-V Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asgar","family":"Rishu","sequence":"additional","affiliation":[{"name":"for the TAPER-V Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle R.","family":"Yee","sequence":"additional","affiliation":[{"name":"for the TAPER-V Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kulikova","sequence":"additional","affiliation":[{"name":"for the TAPER-V Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff E.","family":"Powis","sequence":"additional","affiliation":[{"name":"for the TAPER-V Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Taylor","sequence":"additional","affiliation":[{"name":"for the TAPER-V Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Mertz","sequence":"additional","affiliation":[{"name":"for the TAPER-V Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyue","family":"Dai","sequence":"additional","affiliation":[{"name":"for the TAPER-V Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Chagla","sequence":"additional","affiliation":[{"name":"for the TAPER-V Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenine","family":"Leal","sequence":"additional","affiliation":[{"name":"for the TAPER-V Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elissa","family":"Rennert May","sequence":"additional","affiliation":[{"name":"for the TAPER-V Team"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"16","key":"zoi251619r1","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMra1403772","article-title":"Clostridium difficile infection.","volume":"372","author":"Leffler","year":"2015","journal-title":"N Engl J Med"},{"issue":"10122","key":"zoi251619r2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S0140-6736(18)30320-9","article-title":"A new approach to treating infection.","volume":"391","author":"The Lancet","year":"2018","journal-title":"Lancet"},{"key":"zoi251619r3","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1093\/cid\/cis319","article-title":"Current status of Clostridium difficile infection epidemiology.","volume":"55","author":"Lessa","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"3","key":"zoi251619r4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv076","article-title":"Incidence and costs of Clostridium difficile infections in Canada.","volume":"2","author":"Levy","year":"2015","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"zoi251619r5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/jamainternmed.2015.42","article-title":"Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection.","volume":"175","author":"McDonald","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"5","key":"zoi251619r6","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/cid\/civ958","article-title":"Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection.","volume":"62","author":"Sheitoyan-Pesant","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"zoi251619r7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cmi.2014.08.017","article-title":"Recurrent Clostridium difficile infection is associated with increased mortality.","volume":"21","author":"Olsen","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"zoi251619r8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1017\/ice.2016.246","article-title":"A comprehensive study of costs associated with recurrent Clostridium difficile infection.","volume":"38","author":"Rodrigues","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"zoi251619r9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection.","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi251619r11","first-page":"1058","article-title":"Pseudomembranous colitis: isolation of two species of cytotoxic clostridia and successful treatment with vancomycin.","volume":"119","author":"Marrie","year":"1978","journal-title":"CMAJ"},{"issue":"5","key":"zoi251619r12","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf248","article-title":"Global Practice Variation in the Management of Clostridioides difficile Infections: An International Cross-Sectional Survey of Clinicians.","volume":"12","author":"Prosty","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"zoi251619r13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/jac\/dkv453","article-title":"Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model.","volume":"71","author":"Crowther","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"zoi251619r14","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.","volume":"97","author":"McFarland","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"zoi251619r15","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac138","article-title":"Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?","volume":"5","author":"Patel","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"zoi251619r16","doi-asserted-by":"publisher","DOI":"10.3138\/jammi.2018.02.13","article-title":"Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection.","author":"Loo","year":"2018","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"issue":"5","key":"zoi251619r17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA).","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"zoi251619r18","first-page":"49","article-title":"Allocation of treatments in controlled trials using random permuted blocks.","volume":"54","author":"Ralloc","year":"2000","journal-title":"Stata Tech Bull"},{"issue":"4","key":"zoi251619r19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"zoi251619r20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/MCG.0000000000000473","article-title":"Development and validation of a Clostridium difficile health-related quality-of-life questionnaire.","volume":"50","author":"Garey","year":"2016","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"zoi251619r21","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults.","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"72","key":"zoi251619r22","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.21105\/joss.04284","article-title":"adaptr: an R package for simulating and comparing adaptive clinical trials.","volume":"7","author":"Granholm","year":"2022","journal-title":"J Open Source Softw"},{"key":"zoi251619r23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5840","article-title":"Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis.","volume":"345","author":"Kahan","year":"2012","journal-title":"BMJ"},{"issue":"3","key":"zoi251619r24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/1536867X1601600310","article-title":"Strmst2 and Strmst2pw: new commands to compare survival curves using the restricted mean survival time.","volume":"16","author":"Cronin","year":"2016","journal-title":"Stata J"},{"issue":"3","key":"zoi251619r25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/0016-5085(80)90851-3","article-title":"Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.","volume":"78","author":"Bartlett","year":"1980","journal-title":"Gastroenterology"},{"key":"zoi251619r26","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"zoi251619r28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/cid\/ciz871","article-title":"Use of oral vancomycin for Clostridioides difficile infection and the risk of vancomycin-resistant enterococci.","volume":"71","author":"Stevens","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"zoi251619r29","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1001\/jama.2014.17103","article-title":"Diagnosis and treatment of Clostridium difficile in adults: a systematic review.","volume":"313","author":"Bagdasarian","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"zoi251619r30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/cid\/ciad523","article-title":"Clinical outcomes and management of NAAT-positive\/toxin-negative Clostridioides difficile infection: a systematic review and meta-analysis.","volume":"78","author":"Prosty","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"7","key":"zoi251619r31","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical Practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"zoi251619r27","author":"Johnson","year":"2025"},{"key":"zoi251619r10","unstructured":"Assessment Report: Dificlir (Fidaxomicin). European Medicines Agency. September 22, 2011. Accessed January 1, 2018. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/dificlir-epar-public-assessment-report_en.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2845599\/mcdonald_2026_oi_251619_1772554930.72345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:03:21Z","timestamp":1772557401000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2845599"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.60495","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}